Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer

Bi Dar Wang, Kristin Ceniccola, Sujin Hwang, Ramez Andrawis, Anelia Horvath, Jennifer A. Freedman, Jacqueline Olender, Stefan Knapp, Travers Ching, Lana Garmire, Vyomesh Patel, Mariano Garcia-Blanco, Steven R. Patierno, Norman H. Lee

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Clinical challenges exist in reducing prostate cancer (PCa) disparities. The RNA splicing landscape of PCa across racial populations has not been fully explored as a potential molecular mechanism contributing to race-related tumour aggressiveness. Here, we identify novel genome-wide, race-specific RNA splicing events as critical drivers of PCa aggressiveness and therapeutic resistance in African American (AA) men. AA-enriched splice variants of PIK3CD, FGFR3, TSC2 and RASGRP2 contribute to greater oncogenic potential compared with corresponding European American (EA)-expressing variants. Ectopic overexpression of the newly cloned AA-enriched variant, PIK3CD-S, in EA PCa cell lines enhances AKT/mTOR signalling and increases proliferative and invasive capacity in vitro and confers resistance to selective PI3Kδ inhibitor, CAL-101 (idelalisib), in mouse xenograft models. High PIK3CD-S expression in PCa specimens associates with poor survival. These results highlight the potential of RNA splice variants to serve as novel biomarkers and molecular targets for developmental therapeutics in aggressive PCa.

Original languageEnglish (US)
Article number15921
JournalNature Communications
Volume8
DOIs
StatePublished - Jun 30 2017

Fingerprint

splicing
Alternative Splicing
Drug Resistance
African Americans
Tumors
Prostatic Neoplasms
drugs
tumors
cancer
RNA
RNA Splicing
Pharmaceutical Preparations
Neoplasms
Biomarkers
Phosphatidylinositol 3-Kinases
Heterografts
Genes
Cells
genome
biomarkers

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Wang, B. D., Ceniccola, K., Hwang, S., Andrawis, R., Horvath, A., Freedman, J. A., ... Lee, N. H. (2017). Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer. Nature Communications, 8, [15921]. https://doi.org/10.1038/ncomms15921

Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer. / Wang, Bi Dar; Ceniccola, Kristin; Hwang, Sujin; Andrawis, Ramez; Horvath, Anelia; Freedman, Jennifer A.; Olender, Jacqueline; Knapp, Stefan; Ching, Travers; Garmire, Lana; Patel, Vyomesh; Garcia-Blanco, Mariano; Patierno, Steven R.; Lee, Norman H.

In: Nature Communications, Vol. 8, 15921, 30.06.2017.

Research output: Contribution to journalArticle

Wang, BD, Ceniccola, K, Hwang, S, Andrawis, R, Horvath, A, Freedman, JA, Olender, J, Knapp, S, Ching, T, Garmire, L, Patel, V, Garcia-Blanco, M, Patierno, SR & Lee, NH 2017, 'Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer', Nature Communications, vol. 8, 15921. https://doi.org/10.1038/ncomms15921
Wang, Bi Dar ; Ceniccola, Kristin ; Hwang, Sujin ; Andrawis, Ramez ; Horvath, Anelia ; Freedman, Jennifer A. ; Olender, Jacqueline ; Knapp, Stefan ; Ching, Travers ; Garmire, Lana ; Patel, Vyomesh ; Garcia-Blanco, Mariano ; Patierno, Steven R. ; Lee, Norman H. / Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer. In: Nature Communications. 2017 ; Vol. 8.
@article{dfd60497b87b4f77a938c845a919fdac,
title = "Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer",
abstract = "Clinical challenges exist in reducing prostate cancer (PCa) disparities. The RNA splicing landscape of PCa across racial populations has not been fully explored as a potential molecular mechanism contributing to race-related tumour aggressiveness. Here, we identify novel genome-wide, race-specific RNA splicing events as critical drivers of PCa aggressiveness and therapeutic resistance in African American (AA) men. AA-enriched splice variants of PIK3CD, FGFR3, TSC2 and RASGRP2 contribute to greater oncogenic potential compared with corresponding European American (EA)-expressing variants. Ectopic overexpression of the newly cloned AA-enriched variant, PIK3CD-S, in EA PCa cell lines enhances AKT/mTOR signalling and increases proliferative and invasive capacity in vitro and confers resistance to selective PI3Kδ inhibitor, CAL-101 (idelalisib), in mouse xenograft models. High PIK3CD-S expression in PCa specimens associates with poor survival. These results highlight the potential of RNA splice variants to serve as novel biomarkers and molecular targets for developmental therapeutics in aggressive PCa.",
author = "Wang, {Bi Dar} and Kristin Ceniccola and Sujin Hwang and Ramez Andrawis and Anelia Horvath and Freedman, {Jennifer A.} and Jacqueline Olender and Stefan Knapp and Travers Ching and Lana Garmire and Vyomesh Patel and Mariano Garcia-Blanco and Patierno, {Steven R.} and Lee, {Norman H.}",
year = "2017",
month = "6",
day = "30",
doi = "10.1038/ncomms15921",
language = "English (US)",
volume = "8",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer

AU - Wang, Bi Dar

AU - Ceniccola, Kristin

AU - Hwang, Sujin

AU - Andrawis, Ramez

AU - Horvath, Anelia

AU - Freedman, Jennifer A.

AU - Olender, Jacqueline

AU - Knapp, Stefan

AU - Ching, Travers

AU - Garmire, Lana

AU - Patel, Vyomesh

AU - Garcia-Blanco, Mariano

AU - Patierno, Steven R.

AU - Lee, Norman H.

PY - 2017/6/30

Y1 - 2017/6/30

N2 - Clinical challenges exist in reducing prostate cancer (PCa) disparities. The RNA splicing landscape of PCa across racial populations has not been fully explored as a potential molecular mechanism contributing to race-related tumour aggressiveness. Here, we identify novel genome-wide, race-specific RNA splicing events as critical drivers of PCa aggressiveness and therapeutic resistance in African American (AA) men. AA-enriched splice variants of PIK3CD, FGFR3, TSC2 and RASGRP2 contribute to greater oncogenic potential compared with corresponding European American (EA)-expressing variants. Ectopic overexpression of the newly cloned AA-enriched variant, PIK3CD-S, in EA PCa cell lines enhances AKT/mTOR signalling and increases proliferative and invasive capacity in vitro and confers resistance to selective PI3Kδ inhibitor, CAL-101 (idelalisib), in mouse xenograft models. High PIK3CD-S expression in PCa specimens associates with poor survival. These results highlight the potential of RNA splice variants to serve as novel biomarkers and molecular targets for developmental therapeutics in aggressive PCa.

AB - Clinical challenges exist in reducing prostate cancer (PCa) disparities. The RNA splicing landscape of PCa across racial populations has not been fully explored as a potential molecular mechanism contributing to race-related tumour aggressiveness. Here, we identify novel genome-wide, race-specific RNA splicing events as critical drivers of PCa aggressiveness and therapeutic resistance in African American (AA) men. AA-enriched splice variants of PIK3CD, FGFR3, TSC2 and RASGRP2 contribute to greater oncogenic potential compared with corresponding European American (EA)-expressing variants. Ectopic overexpression of the newly cloned AA-enriched variant, PIK3CD-S, in EA PCa cell lines enhances AKT/mTOR signalling and increases proliferative and invasive capacity in vitro and confers resistance to selective PI3Kδ inhibitor, CAL-101 (idelalisib), in mouse xenograft models. High PIK3CD-S expression in PCa specimens associates with poor survival. These results highlight the potential of RNA splice variants to serve as novel biomarkers and molecular targets for developmental therapeutics in aggressive PCa.

UR - http://www.scopus.com/inward/record.url?scp=85021676602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021676602&partnerID=8YFLogxK

U2 - 10.1038/ncomms15921

DO - 10.1038/ncomms15921

M3 - Article

VL - 8

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 15921

ER -